Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Lindemann

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
British Journal of Pharmacology|April 15, 2014
TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migrationN Nielsen, O Lindemann, A Schwab
Acta Psychologica|November 12, 2022
Spatial-numerical associations without a motor response? Grip force says 'Yes'A Miklashevsky, M H Fischer, O Lindemann
Psychological Research|October 7, 2020
Spatial-numerical associations in the presence of an avatarC Böffel, C Herbst, O Lindemann, et al.
Plos One|June 29, 2023
How to not induce SNAs: The insufficiency of directional forceA Michirev, K Kühne, O Lindemann, et al.
Acta Psychologica|August 29, 2024
Spontaneous grip force fluctuations mirror semantic numerical magnitude processing: Larger numbers elicit larger forcesA Michirev, O Lindemann, K Kühne, et al.
Biochimica Et Biophysica Acta|January 18, 2015
TRPC1 regulates fMLP-stimulated migration and chemotaxis of neutrophil granulocytesO Lindemann, C Strodthoff, M Horstmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJonas Bergh, Per-Ebbe Jönsson, Elisabet Kerstin Lidbrink, et al.
Breast Cancer Research and Treatment|October 16, 2012
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' studyJohn F R Robertson, Justin P O Lindemann, Antonio Llombart-Cussac, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Breast Cancer Research and Treatment|July 16, 2010
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Kathleen I Pritchard, Janusz Rolski, Zsuzsanna Papai, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
British Journal of Pharmacology|April 15, 2014
TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migrationN Nielsen, O Lindemann, A Schwab
Acta Psychologica|November 12, 2022
Spatial-numerical associations without a motor response? Grip force says 'Yes'A Miklashevsky, M H Fischer, O Lindemann
Psychological Research|October 7, 2020
Spatial-numerical associations in the presence of an avatarC Böffel, C Herbst, O Lindemann, et al.
Plos One|June 29, 2023
How to not induce SNAs: The insufficiency of directional forceA Michirev, K Kühne, O Lindemann, et al.
Acta Psychologica|August 29, 2024
Spontaneous grip force fluctuations mirror semantic numerical magnitude processing: Larger numbers elicit larger forcesA Michirev, O Lindemann, K Kühne, et al.
Biochimica Et Biophysica Acta|January 18, 2015
TRPC1 regulates fMLP-stimulated migration and chemotaxis of neutrophil granulocytesO Lindemann, C Strodthoff, M Horstmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancerJonas Bergh, Per-Ebbe Jönsson, Elisabet Kerstin Lidbrink, et al.
Breast Cancer Research and Treatment|October 16, 2012
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' studyJohn F R Robertson, Justin P O Lindemann, Antonio Llombart-Cussac, et al.
Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.
Breast Cancer Research and Treatment|July 16, 2010
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Kathleen I Pritchard, Janusz Rolski, Zsuzsanna Papai, et al.
Pageof 3